NASDAQ: AZRAzora Therapeutics Inc Stock
$4.88-0.17 (-3.37%)
Updated Oct 29, 2026
AZR Price
$4.88
Fair Value Price
$8.80
Market Cap
$12.81M
52 Week Low
$1.31
52 Week High
$8.97
P/E
-0.32x
P/B
-0.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.80M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.75
Operating Cash Flow
-$11M
Beta
0.7
Next Earnings
Nov 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
AZR Overview
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AZR's potential to beat the market
- AZR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AZR
RankedUnranked of 451
RankedUnranked of 451
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.54 | A | |
| $371.56 | A | |
| $10.95 | A |
Be the first to know about important AZR news, forecast changes, insider trades & much more!
AZR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AZR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AZR ($4.88) is undervalued by 44.52% relative to our estimate of its Fair Value price of $8.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AZR ($4.88) is significantly undervalued by 44.52% relative to our estimate of its Fair Value price of $8.80 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AZR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AZR due diligence checks available for Premium users.
Valuation
AZR fair value
Fair Value of AZR stock based on Discounted Cash Flow (DCF)
Price
$4.88
Fair Value
$8.80
Undervalued by
44.52%
AZR ($4.88) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AZR ($4.88) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AZR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AZR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.32x
Industry
15.06x
Market
47.98x
AZR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.33x
Industry
5.21x
AZR's financial health
Profit margin
Revenue
$0.0
Net Income
-$52.0M
Profit Margin
0%
AZR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$29.1M
Liabilities
$28.9M
Debt to equity
-0.75
AZR's short-term assets ($28.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AZR's short-term assets ($28.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AZR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AZR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.4M
Investing
$5.3M
Financing
$25.2M
AZR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AZR vs Biotech Stocks
Azora Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.